Compare Crispr Therapeutics AG (CRSP) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Western Union Co — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.88B), while Western Union Co trades at $6.33 (market cap $1.97B). The key difference: Crispr Therapeutics AG is far larger — about 2.5× Western Union Co's market cap, and Western Union Co pays a 14.85% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Western Union Co for 95 Days on average.
| CRSP | WU | |
|---|---|---|
Market Cap | $4.88B | $1.97B |
Volume | 2,861,747 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $74.92 | $10.28 |
52-Week Low | $44.34 | $5.90 |
Typical Hold Time | 77 Days | 95 Days |
Enterprise Value | $3.30B | $1.88B |
Dividend Yield | — | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Western Union (WU) trades at $6.11, down 0.49% on the day, with the stock showing bearish technical signals and mixed fundamental performance. Recent earnings show two misses in the last three quarters, though the company maintains strong profitability metrics including a 43.97% ROE and 9.79% net margin. The $200 million Beyond Efficiency Plan aims to revive profitability by 2027, while the pending Intermex acquisition faces regulatory hurdles in California.
WU presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, but faces execution risks from margin pressures and acquisition integration. Analyst consensus is cautious with a $6.86 price target, representing 12% upside, though recent technical weakness and earnings volatility warrant careful monitoring of the turnaround plan's progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
